We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chemours (CC) to Post Q4 Earnings: What's in the Cards?
Read MoreHide Full Article
The Chemours Company (CC - Free Report) is set to release fourth-quarter 2019 results after the bell on Feb 13. Results in the company’s Fluoroproducts unit are expected to reflect the impacts of illegal imports and soft demand. The company is also likely to have faced some volume pressure in its Titanium Technologies unit in the quarter. However, Chemours is likely to have benefited from customer adoption of Opteon refrigerants and its productivity actions.
Chemours missed the Zacks Consensus Estimate for earnings in two of the trailing four quarters while beat once and delivered in-line results on the other occasion. In this timeframe, the company delivered a negative surprise of around 11.7%, on an average.
Chemours’ shares are down 63.4% over a year, underperforming the industry’s decline of 27.1%.
What do the Estimates Say?
The Zacks Consensus Estimate for revenues for the fourth quarter for Chemours is currently pegged at $1,370 million, reflecting an expected decline of roughly 6.4% on a year over year basis.
The Zacks Consensus Estimate for revenues for the Fluoroproducts segment for the fourth quarter is pegged at $606 million, indicating a decline of 6.6% year over year.
Moreover, the Zacks Consensus Estimate for revenues for the Chemical Solutions unit stands at $153 million, which reflects an expected 2.7% increase from the prior-year quarter.
The Zacks Consensus Estimate for the Titanium Technologies division is pegged at $608 million, indicating a decline of 8.7% year over year.
Some Factors at Play
Lower volumes are likely to have hurt fourth-quarter sales in the Titanium Technologies segment. Chemours is seeing pressure on Ti-Pure TiO2 (titanium dioxide) pigment volumes. The company witnessed lower volumes for these products through the first half of 2019 as well as in the third quarter due to weak demand. The trend is likely to have continued in the fourth quarter amid a challenging macroeconomic environment.
Chemours is also facing headwinds from illegal imports of HFC refrigerants into the European Union from China. These illegal imports are hurting pricing and volumes of refrigerants. Softer industrial demand, partly due to weakness in automotive and electronics industries, is also affecting the company’s Fluoroproducts unit. These challenges might reflect on sales in this segment in the December quarter.
Nevertheless, the company is expected to have benefited from sustained adoption of Opteon refrigerants in the fourth quarter. Chemours is seeing strong adoption of Opteon for mobile applications. Benefits of the company’s actions to manage costs and drive productivity are also expected to get reflected on fourth-quarter results.
Our proven model does not conclusively predict an earnings beat for Chemours this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But that’s not the case here. Earnings ESP: Earnings ESP for Chemours is 0.00%. This is because the Most Accurate Estimate and the Zacks Consensus Estimate are both currently pegged at 43 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Chemours carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are some companies in the basic materials space you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
Cleveland-Cliffs Inc. (CLF - Free Report) , scheduled to release earnings on Feb 20, has an Earnings ESP of +29.17% and carries a Zacks Rank #3.
AK Steel Holding Corporation , scheduled to release earnings on Feb 20, has an Earnings ESP of +11.11% and carries a Zacks Rank #3.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Chemours (CC) to Post Q4 Earnings: What's in the Cards?
The Chemours Company (CC - Free Report) is set to release fourth-quarter 2019 results after the bell on Feb 13. Results in the company’s Fluoroproducts unit are expected to reflect the impacts of illegal imports and soft demand. The company is also likely to have faced some volume pressure in its Titanium Technologies unit in the quarter. However, Chemours is likely to have benefited from customer adoption of Opteon refrigerants and its productivity actions.
Chemours missed the Zacks Consensus Estimate for earnings in two of the trailing four quarters while beat once and delivered in-line results on the other occasion. In this timeframe, the company delivered a negative surprise of around 11.7%, on an average.
Chemours’ shares are down 63.4% over a year, underperforming the industry’s decline of 27.1%.
What do the Estimates Say?
The Zacks Consensus Estimate for revenues for the fourth quarter for Chemours is currently pegged at $1,370 million, reflecting an expected decline of roughly 6.4% on a year over year basis.
The Zacks Consensus Estimate for revenues for the Fluoroproducts segment for the fourth quarter is pegged at $606 million, indicating a decline of 6.6% year over year.
Moreover, the Zacks Consensus Estimate for revenues for the Chemical Solutions unit stands at $153 million, which reflects an expected 2.7% increase from the prior-year quarter.
The Zacks Consensus Estimate for the Titanium Technologies division is pegged at $608 million, indicating a decline of 8.7% year over year.
Some Factors at Play
Lower volumes are likely to have hurt fourth-quarter sales in the Titanium Technologies segment. Chemours is seeing pressure on Ti-Pure TiO2 (titanium dioxide) pigment volumes. The company witnessed lower volumes for these products through the first half of 2019 as well as in the third quarter due to weak demand. The trend is likely to have continued in the fourth quarter amid a challenging macroeconomic environment.
Chemours is also facing headwinds from illegal imports of HFC refrigerants into the European Union from China. These illegal imports are hurting pricing and volumes of refrigerants. Softer industrial demand, partly due to weakness in automotive and electronics industries, is also affecting the company’s Fluoroproducts unit. These challenges might reflect on sales in this segment in the December quarter.
Nevertheless, the company is expected to have benefited from sustained adoption of Opteon refrigerants in the fourth quarter. Chemours is seeing strong adoption of Opteon for mobile applications. Benefits of the company’s actions to manage costs and drive productivity are also expected to get reflected on fourth-quarter results.
The Chemours Company Price and EPS Surprise
The Chemours Company price-eps-surprise | The Chemours Company Quote
Zacks Model
Our proven model does not conclusively predict an earnings beat for Chemours this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. But that’s not the case here.
Earnings ESP: Earnings ESP for Chemours is 0.00%. This is because the Most Accurate Estimate and the Zacks Consensus Estimate are both currently pegged at 43 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Chemours carries a Zacks Rank #4 (Sell).
Stocks to Consider
Here are some companies in the basic materials space you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
Bunge Limited (BG - Free Report) , scheduled to release earnings on Feb 12, has an Earnings ESP of +18.18% and carries a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cleveland-Cliffs Inc. (CLF - Free Report) , scheduled to release earnings on Feb 20, has an Earnings ESP of +29.17% and carries a Zacks Rank #3.
AK Steel Holding Corporation , scheduled to release earnings on Feb 20, has an Earnings ESP of +11.11% and carries a Zacks Rank #3.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>